<SEC-DOCUMENT>0001193125-14-216578.txt : 20140529
<SEC-HEADER>0001193125-14-216578.hdr.sgml : 20140529
<ACCEPTANCE-DATETIME>20140529114137
ACCESSION NUMBER:		0001193125-14-216578
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140522
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140529
DATE AS OF CHANGE:		20140529

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		14874902

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d735608d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported):&nbsp;May 22, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>DELAWARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36112</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1591613</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9640 Medical Center Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rockville, Maryland </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>20850 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Zip Code)
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(301) 251-5172 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;22, 2014, MacroGenics, Inc.
(the &#147;Company&#148;) entered into a license and option agreement (the &#147;Agreement&#148;) with Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) for the development and commercialization of MGD010. MGD010 incorporates the
Company&#146;s proprietary platform for Dual-Affinity Re-Targeting (DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical
development for the treatment of autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement, the Company will receive an upfront payment of
$15 million and Takeda receives an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study. The Company will lead all product development activities until that time. If Takeda exercises its
option, it will assume responsibility for future development and pay the Company an option exercise fee which, when combined with the upfront payment and an early development milestone, will total $33 million. Assuming successful development and
commercialization of MGD010, the Company could receive up to an additional $468.5 million in clinical, regulatory and commercialization milestone payments. If MGD010 is commercialized, the Company would receive double-digit royalties on any global
net sales and have the option to co-promote MGD010 with Takeda in the United States. In addition, the Company may elect to fund a portion of Phase 3 clinical development in exchange for a North American profit share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement will remain in effect as long as Takeda continues to utilize its rights under the Agreement. Takeda may also terminate the
Agreement at any time upon 90 days&#146; written notice to the Company, if MGD010 has not been commercialized, and upon 180 days&#146; written notice to the Company, if MGD010 has been commercialized. Takeda may also terminate the Agreement in the
event of certain safety concerns, challenges to certain intellectual property rights or in the event of bankruptcy of the Company. The Agreement also contains customary provisions for termination by either party in the event of breach of the
Agreement, subject to cure, by the counter party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of the Agreement is qualified in its
entirety by the terms of the Agreement, which the Company intends to file as an exhibit to its Quarterly Report on Form&nbsp;10-Q for the three months ending June&nbsp;30, 2014. Additionally, on May&nbsp;27, 2014, the Company issued a press release
announcing execution of the license and option agreement with Takeda, a copy of which is filed as Exhibit&nbsp;99.1 to this Current Report. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exhibits to this current report are listed in the Exhibit Index attached hereto and incorporated by reference herein. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MACROGENICS, INC.</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Atul Saran</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Atul Saran</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Senior Vice President and General Counsel</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&nbsp;May 29, 2014 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release, dated May 27, 2014, announcing execution of the license and option agreement between MacroGenics, Inc. and Takeda Pharmaceutical Company Limited.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d735608dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g735608g89o32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MacroGenics and Takeda Enter Strategic Alliance to Develop </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DART for Treatment of Autoimmune Disorders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Option-based collaboration around MGD010 product candidate </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Incorporates MacroGenics&#146; proprietary DART technology for bi-specific targeting of CD32B and CD79B </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MacroGenics has option to co-promote in the United States </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">MacroGenics may participate in funding late-stage development in exchange for North American profit share </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ROCKVILLE, Maryland, May&nbsp;27, 2014 and OSAKA, Japan, May&nbsp;28, 2014 &#150; MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company
focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into an option
agreement for the development and commercialization of MGD010. This product candidate incorporates MacroGenics&#146; proprietary platform for Dual-Affinity Re-Targeting (DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) to
simultaneously engage CD32B and CD79B, which are two B-cell surface proteins. MGD010 is currently in pre-clinical development for the treatment of autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased to be collaborating with MacroGenics, given the company&#146;s expertise in exploring ways to harness the power of the immune system
to treat complex, difficult diseases, including autoimmune disorders. We believe bi-specific antibodies are an important new frontier in medicine that may unlock additional therapeutic options for patients in the future,&#148; said Tetsuyuki
Maruyama, Ph.D., General Manager of the Pharmaceutical Research Division at Takeda. &#147;We look forward to building a long-term strategic collaboration with MacroGenics.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, MacroGenics will receive an upfront payment of $15 million and Takeda receives an option to obtain an exclusive worldwide
license for MGD010 following the completion of a pre-defined Phase 1a study. MacroGenics will lead all product development activities until that time. If Takeda exercises its option, it will assume responsibility for future development and pay
MacroGenics an option exercise fee which, when combined with the upfront payment and an early development milestone, will total $33 million. Assuming successful development and commercialization of MGD010, MacroGenics could receive up to an
additional $468.5 million in clinical, regulatory and commercialization milestone payments. If commercialized, MacroGenics would receive double-digit royalties on any global net sales and has the option to co-promote MGD010 with Takeda in the United
States. Finally, MacroGenics may elect to fund a portion of Phase 3 clinical development in exchange for a North American profit share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are
delighted to enter into this collaboration with Takeda. This partnership represents our fifth DART collaboration and MGD010 represents the first autoimmune DART program planned for clinical development,&#148; said Scott Koenig, M.D., Ph.D.,
President and CEO of MacroGenics. &#147;As a leading global pharmaceutical company, Takeda brings extraordinary expertise in the autoimmune area with significant capabilities in developing and delivering novel medicines to patients. This
collaboration will enable us to further broaden and accelerate our pipeline of innovative DART-based product candidates.&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g735608g89o32.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MGD010 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently approved B-cell-targeted therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections, or
exhibit a delayed onset of action and limited efficacy across patient populations. To address these limitations, MacroGenics is developing MGD010, a humanized DART compound that simultaneously targets CD32B and CD79B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In pre-clinical studies, MGD010 modulates the function of human B cells without B cell depletion. In normal conditions, B cells utilize CD32B as one of the
key negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 exploits this mechanism and triggers this inhibitory &#147;immune checkpoint&#148; loop. MacroGenics believes this molecule
preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote the autoimmune process. Studies in SLE (Systemic Lupus Erythematosus) patient B cells and humanized mouse models have demonstrated that MGD010
can block B cell activation in the absence of B cell depletion. To advance this program to the clinic, MacroGenics completed studies in a non-human primate model with MGD010 demonstrating a favorable safety profile and pharmacological effects on
targeted B cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background on DART Platform </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics&#146; Dual-Affinity Re-Targeting (DART<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) platform enables the targeting of multiple
antigens or cells by using a single molecule with an antibody-like structure. The Company has created over 100 DART-based molecules, or DARTs, which have been configured for the potential treatment of cancer, autoimmune disorders and infectious
disease. These DARTs can be tailored for either short or prolonged pharmacokinetics and have demonstrated good stability and attractive manufacturability. The Company has completed in vitro and in vivo proof of concept pre-clinical studies with
multiple candidates and expects to advance its first two DARTs into clinical development in 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MacroGenics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal
<FONT STYLE="white-space:nowrap">antibody-based</FONT> therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology
platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company creates both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148; which are
drugs designed to improve upon marketed medicines. The combination of MacroGenics&#146; technology platforms and antibody engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic
collaborations with global pharmaceutical and biotechnology companies. <U>www.MacroGenics.com</U> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g735608g89o32.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MacroGenics&#146; Cautionary Note on Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about the company&#146;s strategy,
future operations, clinical development of the company&#146;s therapeutic candidates, milestone or opt-in payments from the company&#146;s collaborators, the company&#146;s anticipated milestones and future expectations and plans and prospects for
the company and other statements containing the words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148;
&#147;target,&#148; &#147;potential,&#148; &#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the
company&#146;s product candidates and other risk factors described in the company&#146;s filings&nbsp;with the Securities and Exchange Commission, including those discussed in the &#147;Risk Factors&#148; section of the company&#146;s most recent
Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> filed with the Securities and Exchange Commission and any subsequent Quarterly Reports on Form 10-Q.&nbsp;In addition, the forward-looking statements included in this press
release represent the company&#146;s views as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause the company&#146;s views to change. However, while the company may elect to update these <FONT
STYLE="white-space:nowrap">forward-looking</FONT> statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company&#146;s views
as of any date subsequent to the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Takeda Pharmaceutical Company Limited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and
one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website,
<U>www.Takeda.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Takeda&#146;s Forward-Looking Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements.&#148; Forward-looking statements include all statements other than statements of historical
fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the
transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing.&nbsp;Statements made in the future tense, and words such as &#147;anticipate,&#148;
&#147;expect,&#148; &#147;project,&#148; &#147;continue,&#148; &#147;believe,&#148; &#147;plan,&#148; &#147;estimate,&#148; &#147;pro forma,&#148; &#147;intend,&#148; &#147;potential,&#148; &#147;target,&#148; &#147;forecast,&#148;
&#147;guidance,&#148; &#147;outlook,&#148; &#147;seek,&#148; &#147;assume,&#148; &#147;will,&#148; &#147;may,&#148; &#147;should,&#148; and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are
based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict.&nbsp;Investors and security holders are cautioned not to place undue reliance on these
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially
from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the
conditions to closing of the transaction may not be satisfied; competitive pressures and </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g735608g89o32.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">developments; applicable laws and regulations; the success or failure of product development programs;
actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained in this press release speak only as of the date of this press release, and neither MacroGenics nor Takeda undertake
any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and
others should not conclude that additional updates or corrections will be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jim Karrels, Vice President, CFO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1-301-251-5172, <U>info@MacroGenics.com</U>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen Sharma, Vice President </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacDougall Biomedical
Communications on behalf of MacroGenics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1-781-235-3060, <U>ksharma@macbiocom.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julia Ellwanger, Senior Director, External Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Takeda Pharmaceuticals International, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1-224-554-7681,
<U>julia.ellwanger@takeda.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Takeda Pharmaceutical Company Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Corporate Communications Dept. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+81-3-3278-2037 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g735608g89o32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g735608g89o32.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`4@+0`P$1``(1`0,1`?_$`-$``0`!!`,!`0$`````
M```````(!@<)"@$$!0(#"P$!``$$`P$!``````````````<!!08(`@,$"0H0
M```&`@(`!`,""`H%#`,```$"`P0%!@`'$0@A$A,),2(405%A@3*4%=58&G&1
MH4)2(S,6-C?18R47"O"QP6)#)$0UM7<8.#1D1Q$``0,#`P(#`P<("`,%"0$`
M`0`"`Q$$!2$&!S$201,(46$B<8&1,A05";'10I(C51<9H5)B,Y/4%E?P<D/!
MLV1U-H*BPF.#H],T=C?_V@`,`P$``A$#$0`_`-_C")A$PBZ[QVV8-'+YXNBU
M9LFZSIVZ<*%10;-6Z9EG#A=4X@1)%%(@F,81X`H".$4'M62UD[)[E'=!'TM"
MZ3UFO*P6JXU%9PR+?IY=%6.GKC((E%/ZF(32.*3<AP$H_*`?,53GF11M/%%.
MD/X_P_?G!$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81!PB@CO2PS._=ADZN:\D%V<"R*UEM^7%@<?+#UX%$U$:.
MR<$$2A,S@@`+$#D2E$`-X%5`'1%-.MUV%J,!$5BNQS>)@X)@VC(J.:D!-!HS
M:I@FBD4`Y\QO*')C"(F.<1,(B(B.$7MX1,(@^/A]^$7C@\,Q=),WIN4G1_38
MO!\`45XY!HX'X%<"`?(/P4#P#Q#@2+V,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?"@^5,
MX\\<$,//CX<%$>?#Q\,J`20!U3IJ%&?>G;OK;UKC#2.\]VT36XBF*S>*G)I$
MUB>ID*`F"-K$>+JR2@B)@#^I;*>(AEBS&Z-O[?#OOF\@@(;XD5^C77W44B\<
M\-\M<NY#[!Q?@<KFKDGXO(M7OC8T$-+B^C6-:"0"2\@>*Q?R/OE:VV%87%2Z
M;=:.RG;>Q$7!$KRJU%Q5:>4P>`J+2LBUDY=FAS\1=,&WAX\Y'#N9L1?DVVV;
M&_R=ST`CB+&D_P!IY'PBFH-#7W+=>V_#9W]M.P9GO4!NS9^P,8Z0`QW^19-=
M/:6]Q,4$!?$YX'_2$[9.@(%:*IF.TO>ZW(1-Q`:%ZH]48&0\QVCO:]UL6P[>
MQ2,(^D#N)JKM=F#H"_E)J-DO'[`#/=#EN5\J!);8_&XN'_Q4KI7?JQ`&I\*Z
M>U8U>[%_#PV#(^TSN\=\;WOVUH["6,6-M@:="Z_+W/%>KV.H000#T5:,^LON
MSV8@#>?<FUQ3Q5*!C,M5]7:JY2;@(?,"$G8WK9XN`<^`G#\6>AV`Y-N']\^=
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MDO.8S>,4M.I[0LD0.0!)%^[B(`JZH>`?.<`$>/'.B6^Y4LW_``6V*R5NWJ89
M'P/)_JD2=WQ>/PZ:KW66-_#HWG$+9V2Y)V5E)/A$]Y%8Y.QC<3XLM6FY>WPK
M\+ODZJW[KWG;[HIVG'=XNA'8GKXWY,1>[UCZ/9-&.H0Q"'71D_0@6I&8CR8H
M)O'*G'V#EK=RO<X:01;RPU]8OT[I&5E@:TUH>]IU=[:#Z%F-M^'UB>2();GT
MT\F[1W=(UA>RRN'NQF2?0ZTMIG3AC?9YCXOD607KW[CW2_L\5LVU%OZE2L^Y
M*D)*=//%*?=?46*`@BG6;42+D7RB7/S"U*NGR'@80S.\#OC:.X0V/$WT+YW5
M^!SJ/&OB#KKX"M5JUROZ6O4'PDYS^2MKY6RQX?VBZC@,]H\]O<>R>W,L1`;J
M2313B1_LR<'%0./`XCSY@^_G[<RQU:ZT!4!,<'-#@>X'QTU^@`?T+],HN281
M,(F$4+J5MV]:OVV[TQON22E&MRDGLEIW:`,V\7'3[9=;U#4N83;D3:,IR,\X
M$1`>!4\"\F\Q#"131Y_D^.$4:.R6Z)'6L#$U.B-"SNX=F.S5S74"EY53HO%@
M]-Y99!/Q!**@4C^J8Y_D,H4`'Y`.(5`UUZ(JET%I:.TK1T(079IJV3#D\_?;
M4OYCO;-:WP"I(/5EE.5C-$55#$;D,/RI^(AYC&$:N=7Y$5\LXHF$3")A%T9*
M/0DV3ADX`?(NF)0,`\'24+\R2R9@^8JB*@`8H_>&$5/569</2/HB3$H3<"X*
MR?!SP+I$P<LY$A?Z#Q$/,/\`UN<(JOPB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6/3N3[E/5KI/
M$+I;8O:<GL!=D9Q#ZDI7HSFPI(3$\[=1U')KD;5N/5/Q_P!ZDEFR8E-R7S_#
M,/W5OK;FRHP_-7#1?=M6Q@$EP]S1[?;T6R?I]](_.?J=R7D\<8=XV\QX;+D+
MLF"PB_YYZ'S'::,M_,=J.X-:>Y:Y%D]S_P!S;W-M@O=,])J0_P!0U)X8R,DZ
MI;DJL]#PBYU&Y9/86XI-LBPJ+5=`_(IQR31<QP$J)EQ`.8`EY.Y"Y)R#L1L.
M$65H!\3R1W@&E27THVFO2IHOKWC/0[Z,O1=M./D/U69G_4F?<T]EF\%ML^5H
M/[.TQK2+BZ!(`\R5SHVNU>YK"LC75/V!]-5!VALCN5<ICLSMR243DI6%D).:
M+KYK)KF%58LBN\<#9;XN14>#+/ET6RO'(MN!\9!VYPCC(>S)[NFFR6<!J2]Y
M=&TC6E'$DCY?H6HW./XIF_\`,V<FP?35C[;87'$`<V)]O##]MF82-1VL%O;$
M@'X8@^36OF=P6>FA42DZWA(^J:^I]9I%=CDRMT(.IP<?7XE!)!'TT0)'Q:#=
ML!P`OB80$PCXB(CDUV]A:8ZV%M8QQQ6[1H&M:T?0T#\B^7V?W3N+>&9DSVZ;
M[(9#-SDF2:]DEFFD/6H>]SJ#Y^F@5>B0@_$A1_A*`_\`1G.@#N\?6]OBK26,
M+>P@%E>E-/H7(``?``#^`,IVM+NX@=WM\54``4&@7'E+\?*7G[^`RG8SV#Z$
MH*UIJN>`^X/XL!C`:@`'Y%7KH>BX\I?Z)?X@RI`)J=2N/:VE*"B\N7BXV88.
MHN7CV4I&/$A1=QTBU;/H]VBH`@HBY9NR*-G*1P_*(<H@.=<T<<T9AG8Q\#A0
MAP#A\X((/T+M@N;BTN675G-);7<+@YDC'%C@X="'-(((]H((\%AC[<^QOT][
M'DDK%0(3_P".6TEA6=M;7K1JBWJ[V1$?437GJ`*J$2J!EQ`3JQYF#@..0./P
MR*]S<.[7S9==XX.Q^9;]26']FWNII\+:#W:4/5?03@'\2SU#\.1#`;JN8MX<
M?./9+9Y(F1XB-0YL-V0Z1M0?B9.)F.H&_"U88;/N#W=?9HG8Z(V!/*;VZZE?
M-V,#+VM66O>M)%DFJ8A(UA:UCENVLIE9#@I&;I8&Y#`/I)+E*)AB6ZS/*W$=
MRT95QR>WJT#G$NTTI\1^)I^6OL)UHOHQ@N-/P_/Q$,7+>[%B.RN:?*\R>UMA
M';W`=1O=+]D%;6^@%*"2`-<T5<]K#2N;+I#[T_5?MN>(I5EE5-%;E?E2;EHN
MP)5HG`STGP(BC2;R8K2*EA<'Y])J[!F^,```)G'@1E[9_,.T=W2BV:399=PT
M9)T-?8:]II\@_*OFGZE?PZ>?/3JR;<,<!W+QJQI=]Y6#2\L93X3=6OQ2V^E2
MZ5I?#IW.>RH"S.E_)+_`'Q^/PR5?"M:K0L=/8N<*J816GW#J:G[HI$A2[6F<
M$5A!W$S#7Y96NSC<!&/FXEP``=%XT5'G@!`JA!,0W@/AU^:SL>^OPL)#M#I3
MK\M/<JT/=V?I4JHLT7LN\TM'VS6'9IY])<]:PBLI7K65,XMMN5)L448M[#B8
M/Z^S'$$TED>?.8W)C<&(H.<RYK6A[C1A!-3H*#4FIIT'54:.\AK>I*JOK;0[
M%9K#,=E]N,S-M@WUL5M2JVX*8Y-<:]4\QXN);$.`BWDI=L8%'!N`.)3<#P90
MY<Y221L<Z(N;W,[:T(/UOJT(J#7W504)(!%6FAU'_!^931\Y?AS_`"#_`">'
MCG$EK?K$`_*%Q#@20*Z==#^9/,7[_P`&<7/:RG=X]/'\BYT*><H?$P!_#X94
M/:?=7VZ?E5#IUT7R*J8#Y1,`#]P\_P#+[<%S&FCBT'WD)I2M13Y0N?.0?@;G
MPY\.1^'\&5#@30&JI4=I=X#YT]0G'//X?@//\7'."X`$^P^&OY%1KVN-`=3[
M=/RJS=PD"U785*L)3>6/LRBE1E^!\I!75X5BEU`^`F36^7D?$"AE15PJ`?H*
MY"C@7-(('O"O)ZA0_*,`"`\?C^[X!E*U<6@&H]Q_,N)>P=2/I7/G+]_V\?;\
M1RA>T"IZ5I_P.JJTAWU?8N!4('')@\?A^'#W!GUJ_03^0*@>PCN!%/E">H3G
MCS>(^/P'_1CN'E^;KV#W&OT4K_0JU:>A'TA<^<OQY_D'_1E`]I;W`Z?T_1U0
MFG5#'*7XCQ\/O^W^#.0(<[M'UJ5^94<YK!5V@)I\Z^05(/\`.^(\!X"'C^,,
MH'AU:5^'KH?S:_,JN<UI`)%3T\?R+Z\Y?OSCYC`[M-0?>"!]-*+E0TKX+ZSF
M"#T5$RJ)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81<<
MA\.0YPJ5`-#U5.6.PPM5AY6QV&5C(.!@V;F2F)N7?-XR,BHUH0ZSQZ_?.CIM
MVK5LDF)CG,(``?;G!\L$<+IK@@1LJ=:4H/Z/G*[;2QR&2OH,?A[=]WF;F811
M1,:YSW%QH&M8T%SB3H`T$DK4W]QOW^7[Y6?TYT6>&8,`,ZC9_L.[:?[1>B(J
M(.4=5Q3I,4V;4P#P69=IBJ80Y;)$^58=9.1^='0%^&V;0R-/:Z[/2,@ZB,$4
M=2E.XU:1T!7W5]&7X4#,M#:<D>I[O$#@V6#!,):Z2-VK?M\C2#&PB@^S1D.=
MTD>TU:<8OM[>VMNOW'-A2>Q[Q.6>"TPSL*CC9>YYY9W+6.Z30K$4D*Y4'DPH
MLI.6$Y#"#IZJ8[:.`P>?S*>1$8WX_P"-<QR+E?O7)R2C!EY+[IQ/>\C4M:":
MU/0FE!5;R>KWUH<7>B+9,&P]AV5E=<B"W`L<-:!D5M91=I#9[L,H(+=OUFPM
MH^0B@[6U<-I&I]T_:B]NP)#JM6-BUG6#W7;Q*.M%>BZG;I^0//E9HJNWMIM$
M17)$;#97!%@,Y65<*J)GY3_JP)Z9=E[?<_&^PN[:S+J*R-L?B;4DU(!HYP[M
M2*5K1?"+,\$>N3U97,7..5PN:W%%FV>=:3N+?)%N2:?8XRX>5!I\#:-:0*BO
M4UB/O;^V<("`]BFOX?+0=C\_9]]2#X9W#ESCVOPY2*OOJ!_2`%;?Y>GK+.AV
M-E@/=Y=1_P"^I*]8^^'5KM_/6>$Z];*#8,A3H]E,60&U6MD*UC&4HNX91YEG
MT_!Q;119VLV4!-,AQ5,"9QX$I1',BV[O/;6Z/,9@)_-=']<`'3QU\!7PUU4-
M<L^G+F7@NVLK_E?!W.#;D7O;!YKV$3F,5=0!Q)[:BI&@)`/53(<>04^#B7CD
M/`QO*'/`@'/CS]N92TN!!974^"A)_P#6:0)&FH_YJ&E5#KLMWDZS]07U+8;\
MV(2G/=AN9!*HQ3>`L-DDY<D<+))XLA'5N+E'2#8CF02)ZBQ2$45/Y2B)@$`L
M.=W7MS;CXXLS<MMII3VLKJ7.]E`"?=4"E:"NJE[B;T^<P<X1Y&7B[!OR..PS
M0;^2H:R,/#G]W<XM;T8XTJ3VM)I0*7,7(-I)HV?MO4*@]9M'J)'")VKDB#M$
MBZ(.&JY4W#9;TU`\Q#E*8AOE$`$,O43V7$#+F*IC>*@T.JB:6-]M<S6DSF]\
M$AC<`06@C31PT(/@:T(U&B]$#D'X'*/V>!@^/W?'!<UKNUQ`<?#Q0@MU=H$`
MY1YX,4>/CP(#QX<^/'P\,Y+C45(KJ.ON^7V+GD/O#":$5\%#_L]W>ZS=/W52
M;]@-B(TQ[L!=XC4F#>%L%DE908DK/ZY4D;6XR4>-FJ*L@BF"JA"$.JH!2B8W
M(!C^=WA@=K/MXLW<"*2Y<1&VE2=0#H-3J>NOL4Q\0^GWF#G=^29Q5A+G*VN*
MC:^\DC<UK(?-#@T%SG!H<6L+NTZT'=2FJO\`SM=IVU:,YKEIK\9:*3=H0B4I
M7+-$)NF,M#2;8BHLY>'DD0$!416`3D4(55)0/@4Y?"Z2V]GE;5T-S"V7'3-J
M[N&C@1[#K[M5%V.RVX-H9R#(82^FQ^Z,?<]T,T3R'L?$Z@(>P^!'4&A'M!6F
MY[JWLI2W7I&P=ANJ4?+672;8RTM=M:D%S*V35"1#&.YEJ^?A5[/41K^48#"9
MY&%\3BHB`J)ZE\J<-C",=N/:;3]W-)+XA4O9W&H+>KNT?T#Q7Z+?09^)CC^4
M7V_#WJ"EB@W_`#!L-IDW=K;*_(`8V"=IHV&Z<10Z>7<._JOHTV?]O+WO-W=5
MEX+6V\UIO>6@TCHL$"OW@/-E:^CS"0GK5:?D%`5L$0R('F_1D@J;@@>5!='P
M*-EV'SAF<$_[OW)W7V&``J?KQ@:#4_6`]^OR]%FOJ_\`PM./>7F7>]>&6Q;=
MY0>'2&-O:W'7[J=S@Z-O_P"G(37]I&.QQ^LRI+QNJ:%W_J;LOKF"VWIFZ1%V
MI,^ERVD&"GD<L'9`*+F(FHU;R2$'-,%/E7:N"$4(/CP)1`1W$Q&<Q.=LFY/#
MW#9K%XT[?`]-1U!]Q`(7YON0^-M\\2[LN]D\D8R7%[KLG=KF2-+0]M3\<9.D
MD;A4MD87-<.AZJ^`&*/P,`_P"`_@_P"?+M[O%8:2`:'K^=0"[H7[:-3DM0U_
M6=H>5EY<)B;C%C,B-A,]<D")1CD%CK-W`^F55X;P`.!$W(_#-$O67R/R=LW)
M;2P/&U\+'(9JZNH7CM!\QQ$;8A4Z"KW@>ZM5LAP!M#9FYK/<>5WK;NN;/&6K
M)6EKG,+&DO#G?"16@:?H]Z_;2ZU&[-:FKEEW7"Q=CM^HK')$DW\@0&J\?)0H
M%>IO'R;0S=,S1TR*0SA!0HMU54!$2>&2?Z9N7+WDCB4YG>$S9]RXJ:2"_`9V
M".6)G>_NK1I';H7?5J"TG185S3Q]%LO?AQ.'J_"7<#);9P->Z.8=K>WVGNK\
MFBCG1NQ6Y[?OK7<B:U/&>M=A[)DH>#K`-616"M;BGQ6!@$IFPK"82+$#U04\
MPJE,(<`'&:9[+]1_,6ZN<]N73LD_^%VY-Q36UM:F&%I$-L\M-7`=X`T-:Z^"
MV'S_``_QO@N-LG:26;Y=[8;"1SW$XE/:R>9O='\(/:[W@#0=5.3L#V0@M#$K
MQ7U?E+/*611\9K%Q;ALV6091J9#NWZZKE-7RH%.L4H>4H\CYO@`#F[7/OJ'V
M[P%C\>_*V<F2RE^^0B*(CN$,;2^27Q^%K0:>!(IU6MO&?%.=Y3?=#&74-E:6
M;@U[Y:AI>^O8P$`U)IIX:A7"INVZM<-71NUDW)HFMNH9Q-R"C\Z8C#I,?6+(
MH/%4A],5F*K8Y3`3\K@.`\0R0-G\G[1W9QJWE&P?Y6VWVTD[G`ZL;%7S`3T!
M!!%-*^"Q7.[-S>W=UOV3>Q/GS++@1`-'5SJ=I'3X34&M.BBZU[QM)9P]DH'3
M6R[!K]B\^C>WE@S\Z#8@G`AG/Z.3:*#Y$RF`QB&<E.4H_,!?AFMV/]:V,S5R
MR[V]M3<5[LHR%KLC%&',91Y8X^6[4N802Y@'=2AIJIAE].N4QY%GEL[A[3<;
MXN^.TFFJZM*@%P':'?/[56M[[7MJ7L-76,3J^Z7N>1A8^<*6NG9BNHSD69)`
M?29G%5UPT;G+ZH\!P(_#,JWWZK,;L[D1O&F+VYG<[NHV#+QK8!!WF*2,24,9
M[7`M802.VM:CP6/;9X9O\]M0;WRN8Q&/PAN'P>9<=[&=\;RPCN[7-U<*#755
MGJ#LU0MJQEP>%2EJB]H:)G%LB+0B1LZB&J97!EW9E4CG(JDB9HH10."*$.7@
M2^(<YAQ5ZD]A\J8_,7<`N\;>X%A=D+:\8&/MPT$NU:*.#:$.U/Q4'56??7$F
MZ]AWUE%>^1=6^2`^R26^L<H);]4]37O80:`4.BLLMWC2>A*S=,TIL6XT:)<*
MH/+BU3(T8$2;AYUUBM19N?*4B7SB"BA#%*(>?R?9$$OK1M+MUQE=G[/SF7VE
M:OD:_(P-#;<-CUD+BX?6;U(&HZ=5G!].N1M9&8[/[BPMCFYHVR"UF>YS_CT#
M06M+:D]14ZZ]%4>SMU:XN_6J5W@UDGS>IT1V6V3:!D4T;`S=5X!%6NI(^99%
M.6D'3E%!$_)DA]<J@"(9L)M'GG96\>+9>5MJSB7#-A?W-<?CBE;3NB>WJUX)
M&AZ@UZ*.[_B?<]AO^VXYR<;&92:=C6EA'EO8_5L@=T+*`DGPI0T*@MJ%GW_[
MM0J^Z"=A2=<M?3;U^6A56I0@.7#V.9.U6@NU3$%NY=,DG"1D@<N'!SN3IF,F
MD0G&0MM'^./,./?O.#.G`[<EF<RVB9$'EX8[L#ZBE6/([JUTJ?8IKW?_``/X
M@OV;.DQ!S^YF0-?<R.E=&UO>`[MH*@.8#2@&H`U)4Q]?S78WK)I[==K[17>,
MW3$ZWCPLM)GZRT;Q=HGH!JP56EF$RBX;,447Z;WTP2.J*@^43#ZA@``R6,#?
M;YXWVAF<MR=>PYBTL#YD3H&]D[HJ#^\%11Q)T!Z-`*C#,6>Q>1=V8?#\86EQ
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M-<#L(EN!ZQ_0Z;8AU"#&FC^`?_4@*7/GY$@\_#,^=R/CSR>>-!;/;F#9BY$Y
MH6.BH32G6I[2/<L%9L#+'CD\CF:/[N^U&V<VI[Q)IKV]*?$#549U^[I4S?$9
MO2:7@I'7L'HB=>1%FEK'),'+-PR8)2R[F:(=B7EJB@C#*F,0P&,("4`Y'PRT
M;$Y:PN_H<S*Z-]K9X><A\CCVT8.\]P^0,<KAO?B;/['N,3;R2QW5WEX:QQL#
MG?$>R@=IU)>!IH5&E#W5H><<RLW1.M&\;SJ6`D3LY;:4+&%%DV10.0KA^:(2
M9.0*BDD?U/35=)J@F("8I!'C,!A]2V.R5P)<+@,U>;=8_M^V,`[:=XC[NP_$
M1W$?-\70*0;KTW93#QBVS.?P5IN)\??]B=(1)_=F3M[Z=@/:--:$_#6I`5W=
MN=]V5-VL.EM3Z6V%OW8<;`,[-:8:FBSCDZW&/V+*2;@X<.F[X[EZ1G(H&6("
M94TC+$3\_J#Y0R3<O.5EB-R.V=@,5?Y?/Q0-FGCCHX1,(#M7:@N`ZM;T6+[>
MX:R&9VTS=^=RECA\#-.Z&"6X>1YKVFA`8T$@$@@.=0>/12_TGLX=PZX@K\I4
M+50G$L9^@\J-UCSQEBA'L:_<1[MH];F*4#%!=L(IJ%`"J)B!@`.<EG:F?=N;
M"QY9UM-:.>2#%*PL>TCV@^'L/0J.-R8([;RTF)^TP7890B6%X?&\'Q!'Y#J%
M=;,D5B3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBM_L
MO8M+U'2;1LG8=DBZI2J;$NIVQS\NX(V91L<T3\ZASG,(&465$`(BD0!476.5
M,@&,8`'PY+(VV,LWW]W(R*VA!+NX@`CY2KQMK;.>W?N&SVOM>TFO]R9"X9#;
MPQL+WESR``UHUZZDZ`"I)`!*T0/=$]VN_P#>.R2.N==J2]"ZQPLAQ%U@QS,Y
MS93AHJ(I6;8'H*^+0ZA?491'(H-2^4ZP*+\"32KDOES)[NE=BL03;;<#R*M-
M'RCI5]-0"/T?I\5^H;T+?AY[3].V,BW_`,C1097G&>W:7/</,AQ43A416C::
MSGI+<#XNZHCHSK9+VR/;ZM'?G>!:ZLH]@=,T0\?-[?N+4O"[>+<+*BPJ,"H8
M>#V:TBV432-P8&S<BJY@'R%*>P<9<>S[ZS1:_O;@('#S7Z@?V6UZ!SJ=*J7O
M7#ZNL)Z2.,3DK/LO.4\TZ1F+LWN[F]S`!)<2-K40V[2'N:-)92&@_$2/Z$>L
M]7T?35#K>L]9UN.J%'I\0A#5VOQ+?T63!DV)Y0^`"HLX7.)E%E5!,JNJ8QSB
M)A$<WTQ>-LL1:LLL:QL6.C:`&=*4]E?;34_.OR0;QW=N7?NY+W>&\KR;(;IR
M,KI)YY"227&IU/0`:-`T``:``%A0]U_5O1'JSUFVKO23ZQZ/G-V[*?OZU19*
M9JD>^FIO9UV*[5<6QV=<P+O3UYL9S++F'S`91$A3#\X9%'*UCLC;NW+S.WMA
M;OR]V',C=0%QE>T]KJD]&FCB1X!?1#T([S]4?./-&`XFQ6]]R6?&>)MV37[(
M)WAEOB[,L<VU:&"C6R`,@C%-3*2`:%8]O:!Z-=9*[U(V5W6[ST^AR]"L9E1I
M:NU(]%W!5JA5)PLTD+8U:.0Y5DKA9#F:M"HE,NX3:$(D4WK``Q]P_LS!V.UK
MC>^\X8OLSJEAE87!L0H"_MH:@G04!TU"W`_$3]5'-66Y]PWIR]-M_DH=UV$;
M!=MQ4CS/<W]VT&*VJQHHRW@I)(7.#6&1QD(\HTDSI#W+M(ZIK6V]C='_`&QM
MDI]5ZE)-W^W-TTUK4-=LG*,"D5!2:3KKMLZ5FU81@\.H9L+T5VZ*@F5(@!C#
MF68[D##6#+B]V5MZ:7;D;OV]S&/*8X=.YK30N`&O0$#4T"@#DGT<<P[\SF$V
MKZC^8L0_G>]B;%B,%>23WTK>\=PMY+II:VU?<2#RZF-S7.'[-\A4_O;M]RB0
M]P0^X;*STB\U)JC5B[-BC?+!<V4N6?EG@.9`8M5DG#1[6.4BJ^B1Z^4!PLF@
M"Z9.1Y$V9EL#?YWJ;F[M+%]KAK5U!*^2H?U)```&@%2:D-J*G5:Q>KWT</\`
M2@_!8+*;GMLUOG.6YE?8VUI,PVS`YL;)!*^1XF$DW?`QH8US@QQH*@+7Y=]I
MM#]NO=&NO;;LEL:"K75+J:DB[UM7II<7TE>B4V4484"#J=01!Q)6*2MUQ!>P
M.TD$C%(@F0BYBI\"$$NW)@MV\G3[ISUY%:X#$?W37`/-P6N(#6M\2^A=4`Z`
M>)7UB_@AR=Z<?0GBN"N(,/>7_//(4E,G-;MH+1L\7=>.N;EW:RV9:VA99->]
M[1YCWEIJZAV%NMO?K:&^XVX[QM/7`_73J%5HJ9L37=6Z[J2%M=KK$2U573G8
MG7[:!,9")4%$51<JO/0](P$1,X5Y`)]PV];O*6\N8N[&7&[1C&DT[NV20?UF
M1=6@UZU^+PJOC_R]Z8\!Q;D\;QYB=UVN[>><A-'%)@\3:&>*UN9G!D5O+D?,
M\N64$]H9%$YXH2\,%"8)2GO*]B-]N=QV;H9U5K]KTKHZ`EK%?]X[SL[JIU]9
MC!LEY0QHV&1D(9NV?24<W.HU8*/5Y!0GE,HBEYP#,'N>5\]GGW<FQL?#/@[!
MA[KNY/EMJ!4M:33XC3X034^[2NT-A^'KQ=Q2W;UAZK=YSXWD;=-Q#':83!Q,
MNKT/DE$(?/+()8S!&]W9*X1M8QX(:^3M)&0/VY^_RO;[J1/]E]N52"THVIMH
MM4':)0\LNC0G,94XR.D7EJBY*:]-RVB4$GYD'":IU?1<MU"`H?,TV)OB+>.U
MSG\LP6GDN<R;6C"6@.+P3X$'Q.G3V+6CU;^EB7T[\\#AK8N1=N:\OX+>2U:V
M,&]!N7O9';7$<3?CN*M!:6#XV/80T=%&`OO7)[3G-A?_`!'Z<[O[,ZVU(@ZD
MM@[6B7L12ZXSAXUNY=/WD&UFFSAP]<_1MCKMVZRB#ERB3SE2\H@.63^+,%_=
M7`VSBKS(V%LW]I.P]D>FI`)&H`!->OC2BEEGX=F5VIA<8_GK?6VME;LSP8W&
M8RY;+=74MP\AD39X[?6VC\PB.25_?$Q_PN<'?"L7'7*R*^[M[HTIVEO[!6M=
M7>KU>AKHWB;>Y:%B("%JQ3O:;"SSHRQX9)W.VA%Y.29P4,D5LS.03"0I<C3`
M7S.5^2_]3W43X-JXB$%K7D=K2T5^-VC072=TA%?JCY5O;RUAF_A[>AV#A+`S
MPW7.W($T]M<2V0<7S2W':V>>%P:V5[+>U\NRM/A!,DQ+1W5"RKN/>GA=BWJZ
MU3IQU1WAVWA-;(NWUWV#3EHJJ5%O',#.#.W4,XFVSQ64(X2:'.R]4K4[XA>4
M"*%'G)'FY:L;V]GBVWB[[)BWKWR1&D+0/TN[44Z^SHM"+7\/#<.T]KX_</J`
MWGMWCNZS`;]@L+P27-_-(\@-$L,9[H&5+>^2KVQEU)0QVB]_HW[M;#O_`+JL
M^J=?]<;77:%4ZL\L=IV-<;7$.THY%SZ#&.AW]4812J"KZ;DE5T$TOK3E%LV5
M5-X!Y<N6Q^4F;XSUSBH+!\=C%&WOD-"T$Z!CW:@%QT;KK316[U0^@K+^D[B[
M&;[WUNO&S[VR>49#9XNTMYJR2,^*29MSY\?[*.,-E<XQ-`D>QI`)6#[WK_:S
M;]=)QUVIT#`>CHJXS(!L&HQ*)@:ZHMTRY'TI*,0*'"%$L[]8")D#@L<]."/`
M)*H@6".:N,8]ORG=&!:]N+F=2:,`_LG$UJ?ZK7'V^*^J/X8_KKFY2QC.`>5;
MALO)%A%7%W<CA7(V<8UB>\FK[RW:"2-731#NZL<3BIZ4]Y]X=%]H-+]J:7^I
M@I!RV3OVMI==PI4-@1"1@!1G*M2&\K&413$?I)%(H.6IO`!,F)TSQ?LC?^;V
M/?BXQY/V)SFF6,]'-!!-*]'4J`?I6]?JB])G%GJHV<-O;V@9;;DA;(ZRR$;&
MF\LY`VO8T]9HNXCSH'5C<WZE'4*_H!]+>YNG.[FHXW;6IY=,@@="/N=)DEFY
M+3K^S"V(JX@;`T((#\QSB9H[3\S=Z@`*)&_+*3?7:^[,3O'%1Y/%/;YCA5T=
M1WMUU#F@U'RD`+\E_/OI]Y']-G(5SQ_R1:B&Y#R^VNFU=!D+<FD5Q!(10>QT
M=>^-U6N`(5M^Y"H!M/JM\0-_O(4'@?#CB6JPAYO'P\2YH_ZQ8Y)^5^*?*&C]
MPD5):T#MGL7'N+B*5#M.M=0L[]/@>-C;]JQWQ8/3I_\`.]_]H'YBHQ;IF+#H
M39F_]<UENJ$7O=E&/8(B`&(5HYL#\0=BS*7P%17ZA\R`I?'YR#]F:X<Q9G<_
M`?(V^^/MN,<S&[V8R:T:"!VNO'=LWE@'ZS7N=&T#4-))UH%+G&V'QW*>T]K[
MNRU'/VD7LN":$R6\3>^.M3KV]K7NKIV@TJ2KF6ZCMM;;BZ/TI$A4S0C1LF_$
M/*`J3#J9*[F%3"7P$ZD@LH//B/&23NC8T/'?+7!^R[&%K&60;)-JUI=/-_>5
M!(<27EU=*THL-VWN2ZWAL/DS=3G&1MRQ[2?!L301'3_E:`*>"\:\;#5O'::V
MV-OKFX;6J>O*])Z[9Q5.8!(%:/I)FZC)"2=G,4Z"2:J[MZ4@_EB8A1#\D!RU
M;WWG=;T]3F5S]CMW)[GV9MG%R8=L=G`;AK9[AKXIG2`D`%O>\M+034#H-1[,
M#M9VW>%+7%3Y&RPF?RV0BOA)=2^5YL$7;+&V,@$EU6-JTT':XZZJW^LK!8U^
MN_9#12C"493U53_O7%P+]!5"9;P@2C!2SQZ[4Q2JE6:)-RJ*$*`^"QOL',&X
MIRVZ&>GOD+A&.WO++.8MIN+6RD:6W/DE_FW43XZF0-(#:4:1[:`K*-\8O%#E
MK9_*)N(WXO*.9%<2L+'QB9C.V.A!Z/.E3TI[=%,7JQN;4$%H"GL92XUJONH"
M.>H6!A(R#5D[1D#23M9=V+)0P.7OUY7!%"&3(IY^>/B`YMSZ5.3^+\;Z<,2W
M(Y3&8[[';R0WD,TL+)!<F5[G/?&7>87R`C3M))&G10-SIL+?-UR[DKR#&WMU
M:SSM=!*QKG1F/M%/B&@+?9T'B0K%WYE>K!W<EDM4S\57[.OKUD[BY:69!(1Y
MV?\`=UNHNU%N=-7A5VD8H$.)!`GQ'[LA#?\`:[^S7K:O#Q??V..W;+MMCK6>
M>-DPEA^R,?VM:7=T?>.CRVAZ*0MMR;>QOICA;O6TN[K;UOEI&7%K%((WNDDN
M2YCN[6K6>YP/=4=-51>L6`3VCNVGJ_IA?>!RN?[\_4JH*"[C6LNNZ>'BFS5!
M$Q2J*-WA7(<"`F`H!P40#,'X[QL>=X9Y@L[EEQ:\W$R_>W=('!XB/F4@8P%[
M6S4D+Z-U>V-M:=,FWXX8GD38VD#>/0R)UD2#W,:\,JR=Q+FDL^#MI[RI0=9-
MLZJ@^L4,26L]=C%:W#3C>R13M^R;R"CWZM^X4\L<JJ5V^-)HKD],2$,"OG`H
M<\"`;->FSEKB3">F.R;D+W&8RUM+"=ES#+-&Q[I7=W>7Q/(>^6>O<10@]U`2
MH>YOV1NV_P"<+W[)9W<D=[=P.M9&M>8_+HRA:]H+0QIK770UJ*:J#S"ERULZ
M)=A8!D11L]V7:0_W:Q9Q,DM8YBKHM[(YA8PAP$JSB0:P:S=$H?VJZ7IEY,(!
MD.>FK96=W!Z;]]RVD#XL??Y*:6Q:UAC$C(FM+3&W]+O[S5PZEH'AI+_(NZ\%
MA/4-M-N4>WR[:".&[>*.,;'AS>YQK0$'45H:'6B_;KM?.NO9'IYK#1^P=XRN
MBK7IQ<B$ZUAKLRUS8'@0AI=!J[3>RGIIRL*]92('63)YE$G:8@<`$/&;N/,W
ML;?'#6*V;N7,2X'*X!K&/I<,MI'F`%K3VEP)J`"01];45JL3W]A-_;!Y@R>Z
MMMX=N:QF9:[RGFU==1ALO:3J&D5;2@IT'3QI9#K)8)B9Z:>XZSD+?8+C&0;1
MRPKSZ?GW\^I^C/T5.(MW#9P^<+@0K]JW25,*8$(H/!@#X9BG&F1R%]Q-OZ&Y
MR$N1MVN>R*:9Y>7`=U"7#N!':1J">BS;DC'V&/Y;V%<Q6+;&]>QDDL<<0B/<
M[L!!CTHX$.T.M#7Q5]?;M8W9G2M&3CSN=6(NB%7F41ZUNF]/2DE`<RDXT;P7
MU[B4+8!</9-<KY,`0\XB8"D\#9F'IU.1_P!-X&_?N^)F-8^0?=I=$"YKR?+9
MJ[OTK74:?*L/]1'W7)N3/6$>T)W9'MC)R8$Q8#&UOF2$!I8:BHK6FAU5G-C:
M"'L1O_W)JY&-_/=:L6B7FAJD\'/]X8%J952-1/QYRGG(X5FH`'`^J<@_S0S#
ML_L;_7^_^1,58_%G[)D-Q;.;H0X/+RT.]IH10:$T%5F&&WW_`*#V+QSFKSX,
M+=NFM[EKOJEA:V,%P]@[@[76@.B[W1O=<AOKN_JZWS/KC;(CK`^HMO.X`Q5'
M5AJ:BK%>0,)N/,>19F174^Y8YP^S.[A;?$V_><L-EKP]N1BV[+#<!P(<9(.]
MCB.M02YI!-*BNB\_,VQ&[#X2S6,L?CQLNXXY;8@@@17':]@/L(:UP(%?#4JB
M="PEAL/53W0(VKMW#N35NQ'7TK4IU'3F.C9N<DYA%%-,!.H)XAHN(E#Q,4!#
M@><M?'UID[WC#DNVM33(LR,C'!M=8XS*7]M!4_"=--:>"O'($]ACN5.-[F[+
M?N]^-9(TNH`))&Q"/NJ:"CP*ZZ:*?'M[=C^N]2Z:T6/G]CT>FOZ&TFVEYBIV
M:C8F4))KSDD^/*_HU=<CV31E&KU)1-9%-7U.?+\2\!//I[WMLK&\-8RUOKZT
MMG67=%.V5[&N\PR&A+2>XAQ+:&E2?!01S_LC>N3YERD]M87=X+U[);=T+'O!
MC\MO0@=H[`#74`4)5K>TFJ*8\VE?^S_6;M;5-2[MJT*`W^KR%FBF3>;/&P+)
M\1J9N\5*[;.YB'3;`+9PT=LW2OIF`$S^8<Q[E'9N-9G+GE'CK<=MA]W6]NYU
MS$9&=DS"W3N:?B#G#Z@[:%U-0KWQINN_9@[7C/D7;=UEMI75R&VDS6.\R%_?
M1YC<W0AA)+R#5HJ5-;V^.P]U[,=>&6P-@QS1I:(^TS=2?2#!L9DRL00S:+73
MGD&8F.DV.Y"0%)8B1A2!=$_EX_)"6^!=^YKD7CZ+.YZ/LR$=Q)`7=O;Y@C#"
M)`/[7<>GL49\X[`PO'&_)<#@93)CI(&3@%W<8S(7@QD]26]@ZZZJ<.30H@3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBUD_^(*TOWFV
ME6J[+ZRC#W#JG2&))RYTR@_7KW9*W(@J96VW>"(45K+6HED4I60,@6*Q.915
M9,!,50NO7.^.WQD,:P8GX]NLUD9'_>?*_P!K:]`/E*^Q/X3G(_IAV#N_(,Y"
MF-CS5?$06%Y>A@LV6SJ!T%G,:MANI'']IY@896T9&[1P.H!1Z59=CW*K4"FQ
M;F<MUTL$55ZW$-2&,XD)J:>(L&#4"@4QB`9PL'G,(""9`,8W@4<U#L\;<9+)
M1V-JUS3+*(VCJ>XFE".O5?HJW7N[;FT=EY#=NXKEK,-B[%]Y<2U$8\F%AF`+
MOJDN:-&M<>XZ#4T6[5[%VJT^N$1W4ZV6-W'/=EZD[#Q#.UO61/3&0AY+7\&-
M>E&Z!Q%S^BG+EN^^F.;P,4W/@)N,W,X3Q+=O-S6WK@TOK:[A\QIT-#$TM=XB
MAH2*$K\QWXG7(-US1F..^;K*.6/9^XMHRSV4;CW""2"]F9<1=PT\PL\ESP-0
M30C19_\`P$OW@(?Q\ADZ]>O1?+RH>W3H5I8>X]?K)[H'N<:SZ7ZFE%'NM]5V
M=QKX\G&\KQK6836!]NS8!Q2,JBHG7(Z,/'(&-P`F8B!1#ULU&Y)O;KDCDJWV
M=8=WW3:/:UY%:#ZOF/.@H&MH`?"J_15Z,-IX;T2>B;,^I_?D+/\`7>=LVWD+
M7#M<Z`AT6'LP?_$2R>?(!KV2-[M6!2L_XA6"LVI.J7572NL(9]"=?*]/NH&;
M;Q*2P1;-S2ZU%,-:Q,X=ND5N5`R"KURF*X^59XEY_F4`,R?GJWOL-L_&X;#L
MD;AHOAE+=&N:UH`:ZAZ5U/AT]B@+\(J^VKR#ZA-[[_Y"NV7?+LULR6T=,1YK
MC=W$DN1FA[NLFD48#:ED!(;0.*BGV2]R"AQ'M:ZWZQ]1M2[+A:=8*+6M7;8V
MK8J3)5VBPLLNQ0D[Y68:PF2,QM5SN\L1Q]2[3.*)&BR@@8ZIRE)C6Y=\6%OQ
M1;;=VU9W444\;&S2>6YK64H7#NZN,A'R4/L4U<+>C_>&<]?&9YEY_P`Y@3FL
M=G+K(XO&07\<M[='S7.L9G6[7>9%:VD8C=V=I/>PMIVAY-!V;W$]:=<O;1HG
M3;J?2-EJVC<-.?,MC[QLE;?4J'>VZX_2J[29T-NZ!24N<J3ZL(-)TD";1LT!
M(4SJ'$H!Y)>0+/!<<6VT=JV]PW*W,5))"QP'>XCO`)'Q.<':=N@I19#A?21N
M_F7ULY3U"<^Y+#V^TL!EN^TQ,-S'=S"UL^\V#KP1UBLXFEGVF2*;]I)(YP#3
M\2CIW&]L.Z=$^MG5SL?.3$G/W*[S[)39-=5B6J->UM.O(R/MM*KR3H!6<.7)
MDV3QJ_6<B1,[Q,")D`./-BVZN,[G8^"Q.Z"YTD\SV&XB+3\#R.\-(H=*`@D^
M_P">=_3QZW=O^JWF3?7"=O:6EGMJQM)ABKGN!N,G$SNM+F>0$@1'O?%)"U@+
MO+%7'V9=O<-[V->^?1>3U9T\U;V'V(_DVE+MNV;-7=26>'U[5*S3P:SMHK+J
M:DV[$)UP,JV2*5")1=IJ)MS?-Y`'F7M][N;OCC]^*VI9WD\_9`92R-P9"P:D
M.=I["V@K7J=%\YO2)Z<(O2[ZJ;7>WJ-S6V,'8V-Q?6^/@NLI;/O[B\F)B@N!
M:L<^1L1C<7-EG[-7-+:.JL<W1C9'7/8W6QGUT[==P&77K1-#N4S.VCKQ0:%:
MZ_?=[RKZ2)*H26Q]FLX^<4G8]-PF1HE&QR"*Z:;9(JA2G(DH&`;'NL#>[79M
M3=V3CL,1#=2&2!H>V>X<XM+22&GX1J*=>FM%M_ZK-H<Q;5YONN;?3YQ[?;PY
M,OL9$VTW!>7=K<8K"PQQ>4!B\>7QADQ:XO=<32.;W%TC&&KP95^Y_P!A+K:^
MD,3KGIOUUV#J'H#59NL5FQ[%G*C)4$+R0OKOH.*K50E"(V]/6XRS0KF2G))%
M,)1^=$IS"`F%3)^3<MECL@8K:&/DMME1TC=+VT,H'0M'7M(H'.(U(/MT@?T*
M\;;/QWJ:GWYZD=VXW/>IVZ@EO++'-N(KU]K*[MCEEN+EA\AE\6N<VVLVN_8L
M$C@&AK`+>T3W'*+HGVCV&ENKNIMDNMER-8E:?O#:!J-)-=<4*S[">2+*Q6:5
MNQ&ZD=.V*;CG`-H=,I_*@3TO4,3T03-X;/?N.VYQ*,7M6RN'WLL1;/(YA[8Y
M'BCWEWB/!H'R=-5G&[?1_NSE+\0^?D/G/-8B/9<.2BN\18-R$4F3R-M9ADEK
M9PV7>UT<#'@R7+NT!U'AO<7U488S=,-1?:+G=(=;:#N>:L^P;?&W#N'NQK0I
M2*UM7(DTJK',-;FMXA_M5-1HPCD!]`!;%0.Y%4P>L)0QFUR?W=Q))@<!;73\
MC?.\VZN&-<&,:'?W;CU-6@--!35U="IMR''^4WK^(K%R'S;E-L6NWL#82V6U
M\/)>0R7=U*&^8V]-I4NBD:Z263]J`7.\CL![`5)_K?[D&K>K?M63.M>MVK-C
M3O8%S'6AOM^^$H\D77U`L=YDWT*VOEHO**)XQV+:N+M6\,T*?S%73*57TTRF
M`V0;>WQ@]L\726^VK.Y=N&XB+;AW8XQL>:M\PO\`ZH_1:/'YU"?-WI"Y!YO]
M?L6[N9\[A+#B)L]I]UV[[^)E_>6=LQDHLK>R<X.#Y;@2>?(!H"2"26A2:]B3
M=&J]?:PJVG]3ZHVWM?<>Y-@R-B[';'C:>K$:XT_`1!'S*L-IN\S*Z#"=2CXY
M$C@C1B8ZRKF17X#S)^0<LX*R>,L,9#C;*UN;K(WKWONI6#X(>PD0EQ=31WZ(
M:216IZJ%/Q4]@[_WAR!D]\;[S.`PG'.W,9%#A,=+>-GR&4FD$3Y_L]BP^;#(
M^322:1HC$5LSKW+,=[L=DK->]N;M>]M)V_T,CJM_!1[5P*0?4V2>D8R.K)4"
MG'Q=EFW*"B8%Y,`D\P>(9*/*+K<;"RXN`"T1`:^TEH`U\:^Q:">@NPS&8]7?
M'PPHE;<LS4-Q)V#XF06S7S70(\`Z$.8[P`-"M"+L[U@V-U3O=<I.PFA@-;]>
M4C9E4F"(*H,IJNW.":2I?2!;Q(]A)([B/>)\B)%VPC^28HCH=N7:^0VQ<10Y
M!K@V>%LK"=.Z-W1S?R4Z@]0OU>\$<^;+Y\VO>[AVD\1FRS5_C)02)'PSV<IB
MJ::C[1"&7$1([7,>-2:A92/8\TGWH=]B:_N?KS&'K6F&KY*$W!:KV:08:UNM
M2!P4TC66+-$`<6RS-A,96/59%,$<[*!U%4RB8IY=X/PV\XL\S*XIDD6V'&DQ
MD%!(SQ:WVN]A%/>:56@7XH_)OIDN.(Y]A\CS_;N52QTF'M[9K'7UC<:M\^=S
M32WMI>W]LV1U;AE`Q@<&N&Y'O!77Z=UT4RN-,"T3$[?5(BH2QG(H!5I4&J<@
M,JJB55,'J9E6J(>GP/B7G[.!D#F]_'+-W;)Q^^<(,QE,CN`P64KG=K;27L#_
M`#7`$%P'8R@'B*E?G<X_L]US83<=SM_("UL;/$A]RQP),\9>&]@H"`=>IITH
MKGVG4=`NMAKUKM-8C)>PU4R9X&47*N"[`R+@KM(2E25317*DZ*"A2JE.!3>(
M9(^Y>)]A[QW/C-X;EQ=K=9_$O/V>5_<2QM>YON<6N`<*U`/M6,8?>&Y-OV%S
MB\-=S6^/N@1(QAHUP+>T@_*"0:4J%V;%JZE6JSUFY3D"R?V6G*&5K<JJ=P5>
M+4.J"QSHE25(B<PJE`P><I@`?'/7N'C79FZ=S6&\<[C+2ZW/BGA]G<O,G?`Y
MI[FEH:X-J#J*U%5TXS<^;PV)N\'C)W0XN^!$\;:=L@/4.%.B_*DZJI6NBRQ:
M9!,H`9Z2-+S)VAG*JDA(F]0/J5E7:RZOF`JIN``Q2E$P\!XYU;*XMV3QT;__
M`$3808_[RO3<SF/N)DD/4N[W.K4Z^P$D@5U5=P[ISNZ'6XSEP^YBM(O+@[SK
M$T"E&4%`*:=.BZK?3]":7E]LAK68Q"Z2K=1I)SQ#N_J7S59!!LNFY;F6,R5]
M9%L0IN4P$P%#D><\\/$''-GOFZY)L<5;Q[UOHC'<W7=)W2L+0TL=&7.A+7@`
M//EAQ`T-5REWANB[V]#M6[NY'8&VD$D4=11CVDN:X'M!%"3X^*H%QU+Z_.9L
M+"KK"N'DP<_6"7_OZ4<+GS^H"@Q:+HD>(>H`")?2\@_=F!77I7X&N\X_=3]L
M8]NX'O\`,/;)<,MW2UT>^!DK8G=34&,C^RLJ',7)@QKL0,Q=_87Q]CA4$N;2
ME.XCN'R@U]ZN,AJ>DHWG_>6$"Q"\_HPL.-@(9R5R$:5`&I6A$O6^E3(5J4$P
M$$P,!0^.21!QELJWWT_D:/&V_P#J\VS8&W'=)WQQ-C$?EL;W>6UM!3X6-=VZ
M56*R;KS\NW';1?<R#;CI?-,(Z>;U[^XCN)]Q/5?A!Z=U_6[=8+S!5MC&6:TI
M+HV"2;*.Q-*%<JIN%_J6RBQV?*JZ8&-Y4R\CSS\1SSX'B78&U]S9+>>`QL,&
MY\IW_:)OB=YH?V=PD:3VN%6Z:>)]I5,EN[<^8PT&W\G=/EQ5K3R0?K1]NC>U
MU*C33JK<2743KY*32LZ\UG`?5*K&<K$;J2;1HHL<PG4.+!H]19`4YAY$I2`4
M1'X?9F#93TL\!YG-2[@R>V[27(3O:]X$EQ'"YP'UC!%*R$N][F'V=-%FMCSE
MRWC<>,59YNX;8-9VM!:Q[@*4_O'`O%!H*'0>]1*[>$;6/;76KK;1"(PZ;>QQ
MMH?LX0`8IPC`KHC>..BFT`GT9F,6Q?.`$.#%Y`_/(\Y.^#Q&,V_:06V)@BM\
M;9M[8H(VAL5*4HYHZ_\`!4875Y?7[[F:^E?-=WAK+,XDRUZU:X]/I4C]@=#^
MINTK`[M-RTO5WL\_<F<R,E&K2U?5DEQ$!.N_2@7\:V<N%3>)U#$$YQ$1,81R
M,,[P?Q=N>_?D\]AK:6^>_N+FNEC[B?ZS8WL;_1KXJ2L%S1R?MO'1XK$YFZ98
M1-[6-<V*3L'L:Z1CG`?/0>`5PJSUAT32Z!9]6U/658@J#=6ZS2W5YB@Y(E8V
MZ[?Z10LN].Y4DWA_IQ$A3G6$R8#\HAF28CCW:&!P=QMW$6$$&(NC^UC;4APZ
M4JXEQ^<E8UF-^;RW!GH=S9K(W%QFK;^[D<0"TCH0&@-%/8!3Q5M8#H%U$JL[
M"6FO:.JD99*[(LIF%ETG=A4<Q\O&K$<L'Z'U$PLD99JX3*8OG(8O(?#,<L.#
M^+<7D8LOC\3''D+<@Q$2S@-<.A[1)VU^04]@60W_`#3RIE<7+A\AEY'V%RTM
MF!CA)<#U`<8N[YR:J]M8TKKRG7J[;,KE8C8N][&*Q"[6-`[T[NP&C``&!G2*
MSE5HF+<?'^J33\W`<YFECM3"X_.76X[.%L68O6!LSV_IAO=2M>OUOZ%A-_N'
M.Y/$6FWK^X=/@[)Q,,;_`-`GMJ10>/;\G2BH^C=5M$:SOTEM*AZUK=9V!,%E
MBR-CCBOB++_IUR1W+^FU4=J,6H/EB`8P))$_B$<LV'XTV=M_,NW%A[**',N9
M*SO`I1LKPYP'LZ*\Y7D+>V<PK=NY?(2SX9KXG>6ZA!=$TM:>E=*Z:].NJJ/6
M.@M5:<-<#ZWIL9537V6&<MI62SYPG-2AA<^9VX(_<NBD$?K%?D(!2?./AERP
M.R]N[7?=R8*W9&Z^D+YP[42.-:DC7K4U'356_.[MW)NJ*UAW#<OF;8QB.`@T
M,;!2C00!TH%9:6]OGJ!,VH;D\T93C39WOZ25]+]+-8E9[ZP.!74@&LBE"#YU
M0Y,7Z?TS"/B4<PBYX!XAN\Q]^386W^\O-$@<'/`#P0ZO8'!AU&M13W+-(><>
M7+7#?<-OF[C[K,1B+'!A)C(IV^86F0:="#7P7K;(Z+=6-M6P]XO>GJU,VAQ]
M,#^536EXI22!F@DV;?I!&'D6+9X9)L@1,!.03>0H`(\`&>G-\)\9[DR\F;S6
M$LILC,UK7O[I6DM9]7X6D,\`#IJ`O%M_E[DS:V*BPF!S-S;XV%SW,91C^UT@
M(=0O:7"M:]>NO526J51K%#KL74J=!15:K4(V*SBH2%9I,(YBW)R/D0;H@!0$
MQA$QC#R8YA$QA$1$<DG%XK'82QCQF)A9;X^(49&P4:T>P?G.JP7(Y+(9>]DR
M65F?<9"5W<^1YJYSCXFOY/!5'EP7B3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PBZ2R!U5!`2$,D;GD!$P`;P('!R_`P"`#R''`Y5M2'
M-D(,9TI3Z5YWL<=6@^:'@MH:-\-74->X>%-.B@.R]MCJS"=JZ]W"JVMF-3VS
M`M[#ZS>O%9L:;-35@;'8&M[VL@B+)K;&#)RN5-VU!N)Q7,HJ514I3AA,?'^T
MXMUC>,%KY>3;5O:*!A=T\[M%0'4^0GQ`*V8R/JVY\RO!-YZ>,QFYLCL&ZFMG
M1FZ+GW-M%;/$HM8I@>XP2.`:6/[J!H`(:2#CX[XH[7]O?MY&^Y1JVHRUWTAL
MJL0VL>XU'@DB*OF+6&.DVK.R&Q"@5)-9JQ11(1TH8$4'#84EC$(\\Y,#WBS)
M[%W?'O\`QL3YL'<L++]H(ZLTB?V?6.GL!I34ZK:WTUR;*]5/I\N?1]N_(6V)
MY6P=[-?[/O+@]D$K[HUN<<YSJ@][R7B,:N#ZL!,7:<M_7KN)UL[35)C;-([;
MJ-Q;/&J*SJ%))-XVW02RB93*,;#5'ZC><AWR!Q$IBJ(^0P@(IG.3@PRIA=T8
M#<%HV_Q-W#+`[V.`<#["TT<".A!'71:*<H\'\L\+9^;;').!R6,RD%:NDA>8
M)&@EOF0SM#H98W$$M<Q[@0KLQE)UY"R1YF&K%/B9A4516E8R%@(^14%R<5'I
MCOV;5%V87AQ$RH^?E01^;GD<NT=OCXKAUU'!"VZ<"#(&`/<#X%U*GYS11]?[
MAW!D+$8R]R-]-CP&#RGW$KHBUOU6B)Q,;1&/J]K13]$A>Q-Q==L+!>,FV4)-
MQS@2BM&RZ#"28+^4P'+Z[-\"S=42&`!#DH@`Y1\-M-6.[8V:)W@]H<`/D/A_
M2O%9Y/(XVX;D,9<W%K?1BC'02/B>!TU>QS'=.H#@O-6JE(=0A:V[KM17KI?1
MXKZT5#K0@`D?U$P+#G1-&D%$X<EX3\!\0\<206LL0MI(X76@_0+`6^[0BB]#
M,[FHLJ=PQWMVW//^M.V:1MQTI_?>87ZCX7?%JTD+J/*307_Z-!_5Z7(IPI2I
M0K=Y!5YPC#HD.14I(TBK02LRE5(!RE2`@`;Q^.<G6N-E:UDL$!#*$'L%01TI
M4&E/<N<.Y=RV<D]S9Y+(1W5S4R>7<2`/KH0^CXS(7`GXI"\CI6FB]:9B:]8X
M]:)GXVO3<8N*9U8^90CY5BL=)3U$C*M'R;EN<R1P`2B)!$#!R'&=DHBN8_+N
MFQR1U^HYH<T>^AT)7CQN0O</>?:,3/<6LD?U)8I7LD^(?'1S',>W7K\>OL7:
MC&,)%-F[-@E&1[1HF5-JSCA:LF;8@";Y$&K<4T4@^8?R2@`AX91I9%'Y$#8F
M0?U0V@/S`=%T2S7%_,^ZR<SYKQ[^XR/<YTKC_;D<YSW?.\JF#ZWU0:5//#0-
M<&G3']0TT>KUD\H=3D3`<TA]`5WZ@"///GYY^W/#]U89[_,DM;?S":D^6RM?
M;6E5D`WEO`0&UCRU_':EH;V"ZN#&6C0-+/,:*4Z`"E%4[UE#R31Q'RB</*1S
MM+T',<^28N(Y=OQQ],X9KE51<(<?S#`)>/LRX/,#XO(<QIMZ4["`01\^GS45
MBM+N\L;X9*RG=;Y!I%)8JL=4=#WAWF!WO#@O$;U.FM(9>LMZ_4T*PZ!0KFNM
M8R&;P2I%`*)R*Q!$DXY8JAB!R!TA#D`'.@6EA';/MK>*!D#M0SRQVD^/<`*+
MVR9[/3Y5F8NK^[DR@.EP9IC/'0&A;,9C(SJ0.P^.M%W6M>J+6'5KK:%KK*NG
M36;#7V[.)1A5&RH`51(8E!,C`4%0`?,42?,`^(#G+R[6&%L,,41C(`<`T!OO
M%"*4]U*+JDS&8N[[[UN;NY^]6R=S+ATLAN&EN@/FAW?K2K3WU`/@=%T6%)U]
M%P;JM1M7ID=7'95TW%=8PL&S@G:2Y?*JF\AFJ"48Z36#P$JB1@'GQSJ;:644
M1M8(;=MH[JT1@#Z*4*]-WN//Y+(LS>1OKN?,Q$&.:::629A'3LE=*Y[?=1S5
M1UGOFB.O5-<25MM&L]/4F(25<N57\E7:=!M`,4QO*BQ3.S17<K%(/D313,HI
M\"@.><WF&P=F]]Q+:06K/`=L8HWW::CQH%>\5A-_\GYR+'8:TRF>W'<N:UK>
MVXO)W.=]5K7#S'>/PM\P4Z+7CVAN::]Z7M#K_KIHN,G2=%]$7F,OV]ML/8]W
M$Q^S9&#6,K'0L>W<HI"BTD$2':QC14OU*H.%'RI$TT4@R"LEFI>8]TV6&P@D
M.S;*427,AJULKFD%K*.H7`$4Z'4D^ROUEV#QO:_AR\+97F'E>:U/JCW3B7X_
M`8LN8^;'17((N+R5K20'BK7S.!HUK1`'%[WM&;+L_P"W_P!;NWD]IV9W=1"V
M-#2[^0=5^(9O!BH^7CI%!LDI5[+](";N1JJ:[!!P#--5$#*I``B*9U"&EO/;
M,P6Z+NVN\_#Y\MC*7Q=`UP=_TW#J6M(!H=#3WT7SPX8]47,WI_Q>X;'BS).L
M9]QV\<5S([XRPQEU)[<$D1W)#G-$O;7L=J:@4EU7*I!4Z&B*U4H2+KE<@VK:
M/B(*$9MXR(BHYL4J:+-A'LTT6S5NBD4`*0A0*'CX>/.99#'%;Q"WMV1QV[10
M-:T`#W`#0*",EDLCF<E<9?,SW%WE;R4RS3RR.DEDE.I+W/))!\=2HP]C_P#-
M#JA_[Q*_^C%_TYJ/ZCW4Y,XL'LW@3_\`9:/_`(_Z/>IHXD_])[Y_\A'_`'K5
M,3-N5!J81,(F$3")A$PBI6[W&`H%3GKE9WI(^!K\:XD)!R<P`;TTB\)H(%'@
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M?5[+::`VUS&V2%W4.U!^9<[6XO+&]9>V4TD4C"'-<QQ;)'(W5DL,@(=&]I`(
M(\17JL*>]O8)Z5[7L3FY:]6OO76T.W)W:RFIYA!*MF<*A_6J-ZQ,M7S:*!0X
MB84V*K5$!'Y2%R(,YPKM#)7)O,7YV-G<-?(<6M)K6M"=/D!`]R^BG&7XG'J)
MV9@8-I[Z^ZM[[:@``CS-NV65S6BC6OG;0RT'1TK'OKJ7%1[_`'<ZGASQW;[#
M`'(_%C%"/'V<\2X<CE@_@1#^_<M^N/SJ7/YK+?\`:'CT_P#T!_\`@3]W/J'[
M;?8;\QBOUOE/X#P_OW+?KC\Z?S66?[0\>_X`_P`NG[N?4/VV^PWYC%?K?'\!
MX?W[EOUQ^=/YK+/]H>/?\`?Y=/W<^H?MM]AOS&*_6^/X#P_OW+?KC\Z?S66?
M[0\>_P"`/\NG[N?4/VV^PWYC%?K?'\!X?W[EOUQ^=/YK+/\`:'CW_`'^73]W
M/J'[;?8;\QBOUOC^`\/[]RWZX_.G\UEG^T/'O^`/\NG[N?4/VV^PWYC%?K?'
M\!X?W[EOUQ^=/YK+/]H>/?\``'^73]W/J'[;?8;\QBOUOC^`\/[]RWZX_.G\
MUEG^T/'O^`/\NG[N?4/VV^PWYC%?K?'\!X?W[EOUQ^=/YK+/]H>/?\`?Y=/W
M<^H?MM]AOS&*_6^/X#P_OW+?KC\Z?S66?[0\>_X`_P`NG[N?4/VV^PWYC%?K
M?'\!X?W[EOUQ^=/YK+/]H>/?\`?Y=5I1?^'0ZN1\^TG-O[DWIN])F8AR0LY.
M,*W&K@F8!(DY<1#=Q.F0$`X,5)ZER'ASGJL>!\"V=LN<O;W(1M-0R1U&_/0D
M]/80L;W+^+#S*<7)B^*=M;2V8)A\<MA:=TM>O<WN#8JUZ=T3EF[U)I+6.B*7
M%Z[T_1ZQKNE0R1@8U^L1J<>T^H4_MG[Q0G+F3D7`%#U7+@ZJZ@AR8P^&3-BL
M3BL'8#'8N$0VP_JTK3Y5\V]^[^WUR;N:XW;OO*7.6SMP*NFNGF23N))[14]L
M<0K\,48:QO@`-%=K/<L43"*'?8__`#1ZH_\`O$I_Z,3-1/4A_P#Z=Q;_`/UY
M_P"ZB4Y\2?\`I/?/_D(_[T*8F;=J#$PB81,(F$3"+RYJ:BJ[%/YR=D641#1;
M55Y(R<@Y3:,F;9$OF46775,4J90#\8CP`>(@&$6)VXV6Y=^]E(:^H(R->Z[T
MJ31=6>UJ(J(#8'*!Q\BY2'\H*.UT@,6.:&^9$#"X6`/E*7G]3Y5195JI5H*D
MUN%J598)1<#7X]O&1;%$``B#5N3REY'XJ*JFY.H<?F.<PF'Q$<XDU-555!E$
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MRU@+=I'A\0=7K[NNOR*0N3RH[7R<X)D.<0,8"%$WE(43'-P'/!"AXF,/V`'B
M(X14LSO%2>.ACRV"-0DRF\IHJ07+%RI3?T1C)$6ST>!\.0((?APBJKGD.0$!
M`?@/Q#*&M-.J+R)>P0-?;G=STW$0K5,HF.YEI)G'($*'Q$RKQ9%,`_'AO>3K
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M\Z[.>M<T'X#\?Q?'\7X<(K&[T_PS_P#QW^S4_P`X/_+/A_X/_6X18E+9_P!K
M_B[\I3_)3_#?Q'_\7_\`6^[\6<F?6\/G16!2_P`0H?X/_MR?_83\C^U_\1_J
MONSN*IX+-?U@_P`+)_\`UZ_L"_Y%_D_$/_,_];_2SK=\_P`Z*5F=:JF$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
I81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
